Fractyl Health (GUTS) Shares Outstanding (Weighted Average) (2023 - 2026)
Fractyl Health (GUTS) reported Shares Outstanding (Weighted Average) of $21.1 million for Q1 2026, down 56.72% year-on-year from $48.9 million in Q1 2025, and down 72.11% quarter-over-quarter from $75.8 million in Q4 2025.
Fractyl Health (GUTS) has 4 years of Shares Outstanding (Weighted Average) data on file, last reported at $21.1 million in Q1 2026.
- For the quarter ending Q1 2026, Shares Outstanding (Weighted Average) fell 56.72% year-over-year to $21.1 million; the trailing twelve-month figure through Mar 2026 stood at $21.1 million (down 56.72% YoY), and the FY2025 full-year result was $75.8 million, up 74.13% from the prior year.
- Shares Outstanding (Weighted Average) for Q1 2026 stood at $21.1 million, down from $75.8 million in the prior quarter.
- Across five years, Shares Outstanding (Weighted Average) topped out at $75.8 million in Q4 2025 and bottomed at $2.1 million in Q1 2023.
- A 4-year average of $33.1 million and a median of $41.9 million in 2024 frame the typical range for Shares Outstanding (Weighted Average).
- Across the five-year window, Shares Outstanding (Weighted Average) soared 2218.19% in 2024 and sank 56.72% in 2026, its largest moves.
- Tracing GUTS's Shares Outstanding (Weighted Average) over 4 years: stood at $2.1 million in 2023, then jumped by 1992.01% to $43.5 million in 2024, then surged by 74.13% to $75.8 million in 2025, then plunged by 72.11% to $21.1 million in 2026.
- According to Business Quant data, Shares Outstanding (Weighted Average) over the past three periods registered $21.1 million, $75.8 million, and $64.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Weighted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,638,563.89 Bn | 1,638,563.89 Bn | - | 177,333.76 Bn |
| 2 | Alterity Therapeutics | 767,934.24 Bn | 767,934.20 Bn | - | 185,491.37 Bn |
| 3 | Legend Biotech | 2,937.00 Bn | 2,936.10 Bn | 242.10 Mn | 100.00 Bn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | 55.66 Bn |
| 5 | Akari Therapeutics | 2,169.69 Bn | 2,169.69 Bn | - | 118.76 Bn |
| 6 | Vertex Pharmaceuticals | 110.41 Bn | 103.16 Bn | 2.59 Bn | 254.10 Mn |
| 7 | Regeneron Pharmaceuticals | 66.44 Bn | 57.69 Bn | 3.31 Bn | 104.00 Mn |
| 8 | Evaxion A | 65.44 Bn | 65.42 Bn | - | 16.04 Bn |
| 9 | Alnylam Pharmaceuticals | 39.53 Bn | 36.52 Bn | 959.66 Mn | 132.89 Mn |
| 10 | Fractyl Health | 19.24 Mn | 19.24 Mn | - | 21.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 21.15 Mn |
| Dec 31, 2025 | 75.82 Mn |
| Sep 30, 2025 | 64.65 Mn |
| Jun 30, 2025 | 48.95 Mn |
| Mar 31, 2025 | 48.87 Mn |
| Dec 31, 2024 | 43.54 Mn |
| Sep 30, 2024 | 41.89 Mn |
| Jun 30, 2024 | 47.90 Mn |
| Mar 31, 2024 | 29.74 Mn |
| Dec 31, 2023 | 2.08 Mn |
| Sep 30, 2023 | 2.07 Mn |
| Jun 30, 2023 | 2.07 Mn |
| Mar 31, 2023 | 2.06 Mn |